Skip to content
10-Q

Quarterly Report

PSYCHEMEDICS CORPORATION

0001171843-24-002876

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 10, 2024 5.81M sh
Capex Q1 2024 · Mar 31, 2024 $0
Capex Q1 2024 · Mar 31, 2023 $20K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$473K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$225K
Short Term Debt Q1 2024 · Mar 31, 2024 $230K
Short Term Debt Q1 2024 · Dec 31, 2023 $305K
Cash And Equivalents Q1 2024 · Mar 31, 2024 $1.42M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $1.96M
Stockholders Equity Q1 2024 · Mar 31, 2024 $6.28M
Stockholders Equity Q1 2024 · Dec 31, 2023 $6.67M
Stockholders Equity Q1 2024 · Mar 31, 2023 $10.17M
Stockholders Equity Q1 2024 · Dec 31, 2022 $10.77M
Current Liabilities Q1 2024 · Mar 31, 2024 $4.18M
Current Liabilities Q1 2024 · Dec 31, 2023 $4.71M
Total Liabilities Q1 2024 · Mar 31, 2024 $4.87M
Total Liabilities Q1 2024 · Dec 31, 2023 $5.65M
Current Assets Q1 2024 · Mar 31, 2024 $6.19M
Current Assets Q1 2024 · Dec 31, 2023 $6.81M
Total Assets Q1 2024 · Mar 31, 2024 $11.15M
Total Assets Q1 2024 · Dec 31, 2023 $12.33M
Eps Basic Q1 2024 · Mar 31, 2024 −$0.12
Eps Basic Q1 2024 · Mar 31, 2023 −$0.07
Sga Expense Q1 2024 · Mar 31, 2024 $1.79M
Sga Expense Q1 2024 · Mar 31, 2023 $1.65M
Rd Expense Q1 2024 · Mar 31, 2024 $209K
Rd Expense Q1 2024 · Mar 31, 2023 $298K
Net Income Q1 2024 · Mar 31, 2024 −$688K
Net Income Q1 2024 · Mar 31, 2023 −$384K
Operating Income Q1 2024 · Mar 31, 2024 −$567K
Operating Income Q1 2024 · Mar 31, 2023 −$528K
Gross Profit Q1 2024 · Mar 31, 2024 $2.12M
Gross Profit Q1 2024 · Mar 31, 2023 $2.21M
Cost Of Revenue Q1 2024 · Mar 31, 2024 $3.24M
Cost Of Revenue Q1 2024 · Mar 31, 2023 $3.65M